Background: In light of the limited supply of intravenous immunoglobulins, it is important to strive for their appropriate use. Off-label use needs to be discouraged because of the limited supply of intravenous immunoglobulins, their unproven effectiveness in many conditions, their high costs, and the risk of adverse effects. This study aims to document the use of intravenous immunoglobulins in registered and off-label conditions in Belgian hospitals. Methods: Data were derived from the IMS Health hospital disease database. For each condition, this database generated figures about the number of patients and the reimbursement value in 2007. Data were provided at the level of individual products. Results: In 2007, intravenous immunoglobulins were administered to 9,629 patients, amounting to a reimbursement value of EUR 33.5 million (or 17% of Belgian hospital drug expenditure). Around 50–60% of intravenous immunoglobulin use was associated with registered conditions and around 40–50% with off-label use, depending on how use was measured. Off-label use occurred in unspecified conditions, surgery, orthopedics and oncology. There was limited use in myasthenia gravis. The market was dominated by Multigam and Sandoglobuline, each of which made up 45–50% of intravenous immunoglobulin use. Conclusions: In addition to their use in registered conditions, intravenous immunoglobulins are used off-label in other conditions in Belgium. A number of options are proposed to discourage off-label use in light of the limited supply of intravenous immunoglobulins, their unproven effectiveness in many conditions, their high cost, and the risk of adverse effects.

Keywords:
Immunoglobulins, intravenous, Off-label use, Reimbursement, Belgium
1.
Kallenberg CGM, Laseur M: Cost considerations in choosing an intravenous immunoglobulin preparation. Eur J Hosp Pharm Pract 2007;13:6–7.
2.
Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA: A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000;34:295–299.
3.
Kumar A, Teuber SS, Gershwin ME: Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol 2006;140:185–198.
4.
Darabi K, Abdel-Wahab O, Dzik WH: Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46:741–753.
5.
Alangari AA, Abutaleb MH, Albarraq AA, Al-Dhowailie AA: Intravenous immunoglobulin utilization in a tertiary care teaching hospital in Saudi Arabia. Saudi Med J 2008;29:975–979.
6.
Sacher RA: Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol 2001;108:S139–S146.
7.
Bjorkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ: Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang 2006;90:286–293.
8.
Simoens S: Pharmaco-economics of immunoglobulins in primary immunodeficiency. Expert Rev Pharmacoecon Outcomes Res 2009;9:375–386.
9.
Constantine MM, Thomas W, Whitman L, Kahwash E, Dolan S, Smith S, Caudle CJ, Burton E, Anderson DR: Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group. Transfusion 2007;47:2072–2080.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.